Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interferon-Free Hepatitis C Regimens Within Reach

Executive Summary

Much of the hep C wish list was on display at the American Association for the Study of Liver Disease meeting in Boston Nov. 10-13 – all-oral interferon-free drug combinations for hepatitis C, regimens that don’t require ribavirin, and the possibility of a one-pill, once-a-day cure – demonstrating the Gold Rush mentality in the hep C space as drug makers race to put the pieces together and grab a share of a burgeoning market.

You may also be interested in...



Data For Gilead’s Rising Hep C Star Sofosbuvir Support Initial Filing

Gilead reported results from three Phase III trials in February, with data strong enough to support U.S. and European filing for sofosbuvir, the nucleoside it plans eventually to make the foundation of a fixed-dose pill available by 2015.

Data For Gilead’s Rising Hep C Star Sofosbuvir Support Initial Filing

Gilead released Phase III data Feb. 4 strong enough to support U.S. and European filing for sofosbuvir, the nucleoside it plans eventually to make the foundation of a fixed-dose pill available by 2015.

Gilead Phase III Program For Two-Drug HCV Combo On Faster Pace Than Expected

Company also updates Phase II ELECTRON data from November, showing all nine patients in a null-responder cohort achieved sustained virological response after four weeks of therapy with combo.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054902

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel